{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:43:27Z","timestamp":1791431007273,"version":"4.3.3"},"reference-count":45,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Oradea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Accurate and rapid diagnosis of drug-resistant tuberculosis is essential for initiating appropriate treatment and preventing the transmission of these strains. This study compares phenotypic and genotypic methods of drug susceptibility testing for Mycobacterium tuberculosis (M. tuberculosis). Methods: Resistance to first-line drugs, as well as resistance to second-line drugs (fluoroquinolones and aminoglycosides), was assessed using the L\u00f6wenstein\u2013Jensen medium phenotypic method and the GenoType MTBDRplus genotypic method and analyzed. Results: The phenotypic resistance rate was 84.85% for INH (n = 56), 46.97% for RIF (n = 31), 48.48% for STR (n = 32), and 30.30% for EMB (n = 20). Of the MDR-TB isolates (n = 29), 41.37% were resistant to fluoroquinolones (n = 12) and 31.03% were resistant to both fluoroquinolones and injectable aminoglycosides, being classified as XDR-TB (n = 9). In addition, 22.73% of the MDR-TB isolates were resistant to all four first-line drugs (n = 15). The overall concordance between the line probe assay method and phenotypic testing was 94.74% for RIF and 95.16% for INH. Discordances were identified in three cases for RIF and two cases for INH, where isolates were reported as susceptible by GenoType MTBDRplus, but phenotypically resistant. Conclusions: Genotypic testing using GenoType MTBDRplus provides rapid and accurate results, but some cases of phenotypic resistance are not detected by this method. The results highlight the importance of using combined phenotypic and genotypic methods for accurate diagnosis of MDR-TB, as well as the need to integrate genomic sequencing to improve diagnostic accuracy.<\/jats:p>","DOI":"10.3390\/antibiotics14070732","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T10:35:31Z","timestamp":1753094131000},"page":"732","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genotypic and Phenotypic Methods in the Detection of MDR-TB and Evolution to XDR-TB"],"prefix":"10.3390","volume":"14","author":[{"given":"Natalia","family":"Zaporojan","sequence":"first","affiliation":[{"name":"Doctoral School of Biomedical Sciences, University of Oradea, University Street 1, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7507-5072","authenticated-orcid":false,"given":"Ramona","family":"Hodi\u0219an","sequence":"additional","affiliation":[{"name":"Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 1 December Square 10, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Panti\u0219","sequence":"additional","affiliation":[{"name":"Department of Surgical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 1 December Square 10, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei Nicolae","family":"Csep","sequence":"additional","affiliation":[{"name":"Department of Psycho-Neurosciences and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 1 December Square 10, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu","family":"Zaporojan","sequence":"additional","affiliation":[{"name":"Doctoral School of Biomedical Sciences, University of Oradea, University Street 1, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-4989","authenticated-orcid":false,"given":"Dana Carmen","family":"Zaha","sequence":"additional","affiliation":[{"name":"Doctoral School of Biomedical Sciences, University of Oradea, University Street 1, 410087 Oradea, Romania"},{"name":"Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 1 December Square 10, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"ref_1","unstructured":"WHO (2023). Global Tuberculosis Report 2023, World Health Organization. Available online: https:\/\/iris.who.int\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e02236-24","DOI":"10.1128\/spectrum.02236-24","article-title":"Discordance in genotypic and phenotypic drug susceptibility results: Time to reconsider critical concentration of rifampicin","volume":"13","author":"Shrivas","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_3","unstructured":"WHO (2022). Annual Report of Tuberculosis, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240061729."},{"key":"ref_4","unstructured":"(2025, July 10). Tuberculosis Surveillance and Monitoring in Europe 2025\u20132023 Data. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/tuberculosis-surveillance-and-monitoring-europe-2025-2023-data."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2147\/IDR.S289907","article-title":"Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study","volume":"14","author":"Cheng","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","article-title":"Management of drug-resistant tuberculosis","volume":"394","author":"Lange","year":"2019","journal-title":"Lancet"},{"key":"ref_7","unstructured":"WHO (2025, February 04). Drug-Resistant TB Treatment. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240063129."},{"key":"ref_8","unstructured":"(2025, February 25). WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment\u2014Drug-Resistant Tuberculosis Treatment, 2022 Update, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK588564\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2100361","DOI":"10.1183\/13993003.00361-2021","article-title":"New definitions of pre-extensively and extensively drug-resistant tuberculosis: Update from the World Health Organization","volume":"57","author":"Viney","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bu, Q., Qiang, R., Fang, L., Peng, X., Zhang, H., and Cheng, H. (2023). Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1156249"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Naidoo, K., Perumal, R., Ngema, S.L., Shunmugam, L., and Somboro, A.M. (2023). Rapid Diagnosis of Drug-Resistant Tuberculosis-Opportunities and Challenges. Pathogens, 13.","DOI":"10.3390\/pathogens13010027"},{"key":"ref_12","unstructured":"Timi\u0219oara Regional Public Health Center, National Center for Health Assessment and Promotion, and National Institute of Public Health (2025, February 24). Situation Analysis\u2014National Communicable Diseases Awareness Month Campaign: Tuberculosis, HIV, Hepatitis; Region I, Available online: https:\/\/www.dsptimis.ro\/promovare\/bt_20_analiza.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rahman, S.M.M., Nasrin, R., Rahman, A., Ahmed, S., Khatun, R., Uddin, M.K.M., Rahman, M.M., and Banu, S. (2021). Performance of GenoType MTBDRsl assay for detection of second-line drugs and ethambutol resistance directly from sputum specimens of MDR-TB patients in Bangladesh. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0261329"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e01550-17","DOI":"10.1128\/AAC.01550-17","article-title":"What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis","volume":"62","author":"Heyckendorf","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.2147\/IDR.S468997","article-title":"Discordance Between Phenotypic and WGS-Based Drug Susceptibility Testing Results for Some Anti-Tuberculosis Drugs: A Snapshot Study of Paired Mycobacterium tuberculosis Isolates with Small Genetic Distance","volume":"17","author":"Sadovska","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Singhal, R., Anthwal, D., Kumar, G., Sah, G., Salfinger, M., Choudhury, S., Arora, J., Bhalla, M., Myneedu, V.P., and Sarin, R. (2020). Genotypic characterization of \u2018inferred\u2019 rifampin mutations in GenoType MTBDRplus assay and its association with phenotypic susceptibility testing of Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis., 96.","DOI":"10.1016\/j.diagmicrobio.2020.114995"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bokop, C., Faye, L.M., and Apalata, T. (2023). Analysis of Discordance between Genotypic and Phenotypic Assays for Rifampicin-Resistant Mycobacterium tuberculosis Isolated from Healthcare Facilities in Mthatha. Pathogens, 12.","DOI":"10.20944\/preprints202304.0074.v1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2147\/IDR.S457308","article-title":"Identification of Mycobacterium tuberculosis Resistance to Common Antibiotics: An Overview of Current Methods and Techniques","volume":"17","author":"Xiong","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Tilahun, M., Wegayehu, T., Wondale, B., Gebresilase, T.T., Gebreyohannes, T., Tekola, A., Alemu, M., Neway, S., Adnew, B., and Nassir, M. (2023). Phenotypic and genotypic drug susceptibility patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Central and Southern Ethiopia. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0285063"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102083","DOI":"10.1016\/j.tube.2021.102083","article-title":"Mechanisms and detection methods of Mycobacterium tuberculosis rifampicin resistance: The phenomenon of drug resistance is complex","volume":"128","author":"Xu","year":"2021","journal-title":"Tuberculosis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","article-title":"Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis","volume":"5","author":"Seung","year":"2015","journal-title":"Cold Spring Harb. Perspect Med."},{"key":"ref_22","unstructured":"WHO (2023). Catalogue of Mutations in Mycobacterium Tuberculosis Complex and Their Association with Drug Resistance, World Health Organization. [2nd ed.]. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240082410."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lv, H., Zhang, X., Zhang, X., Bai, J., You, S., Li, X., Li, S., Wang, Y., Zhang, W., and Xu, Y. (2024). Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09079-5"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5588\/ijtldopen.24.0357","article-title":"The impact of the war in Ukraine on the prevalence of MDR\/RR-TB in Poland","volume":"2","author":"Nowinski","year":"2025","journal-title":"IJTLD Open"},{"key":"ref_25","unstructured":"WHO (2024, December 31). Tuberculosis Resurges as Top Infectious Disease Killer. Available online: https:\/\/www.who.int\/news\/item\/29-10-2024-tuberculosis-resurges-as-top-infectious-disease-killer."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Huyen, M.N., Tiemersma, E.W., Lan, N.T., Cobelens, F.G., Dung, N.H., Sy, D.N., Buu, T.N., Kremer, K., Hang, P.T., and Caws, M. (2010). Validation of the GenoType\u00ae MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect. Dis., 10.","DOI":"10.1186\/1471-2334-10-149"},{"key":"ref_27","first-page":"75","article-title":"Genotype MTBDRplus Assay Detection of Rifampicin and Isoniazid Resistant Mycobacterium tuberculosis in Morocco","volume":"7","author":"Aainouss","year":"2024","journal-title":"Acta Sci. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3855\/jidc.18945","article-title":"Synergy of Xpert (MTB\/RIF) and Line probe assay for detection of rifampicin resistant strains of Mycobacterium tuberculosis","volume":"18","author":"Hussain","year":"2024","journal-title":"J. Infect. Dev. Ctries"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijtb.2021.05.003","article-title":"Tuberculosis with discordant drug resistance patterns- A diagnostic dilemma","volume":"69","author":"Gupta","year":"2022","journal-title":"Indian J. Tuberc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1128\/JCM.00417-14","article-title":"Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States","volume":"52","author":"Yakrus","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yusoof, K.A., Garc\u00eda, J.I., Schami, A., Garcia-Vilanova, A., Kelley, H.V., Wang, S.H., Rendon, A., Restrepo, B.I., Yotebieng, M., and Torrelles, J.B. (2022). Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.870768"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cmi.2023.07.013","article-title":"Recent advances in the treatment of tuberculosis","volume":"30","author":"Motta","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.cmi.2020.07.004","article-title":"Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens","volume":"26","author":"Whitfield","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Seifert, M., Catanzaro, D., Catanzaro, A., and Rodwell, T.C. (2015). Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: A systematic review. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119628"},{"key":"ref_35","first-page":"MGM2-0014-2013","article-title":"Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities","volume":"2","author":"Jacobs","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4046\/trd.2020.0039","article-title":"Diagnostic Evaluation of Non-Interpretable Results Associated with rpoB Gene in Genotype MTBDRplus Ver 2.0","volume":"83","author":"Singh","year":"2020","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_37","first-page":"556","article-title":"Mutation Profile Assessment of rpoB, KatG and inhA Genes in Rifampicin and Isoniazid Resistant Mycobacterium tuberculosis in India","volume":"9","author":"Yadav","year":"2020","journal-title":"JSRG"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JCM.00553-13","article-title":"Rifampin drug resistance tests for tuberculosis: Challenging the gold standard","volume":"51","author":"Aung","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sirgel, F.A., Warren, R.M., B\u00f6ttger, E.C., Klopper, M., Victor, T.C., and van Helden, P.D. (2013). The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059414"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/JCM.00691-14","article-title":"Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis","volume":"52","author":"Jamieson","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e01885-20","DOI":"10.1128\/JCM.01885-20","article-title":"Low-Level Rifampin Resistance and rpoB Mutations in Mycobacterium tuberculosis: An Analysis of Whole-Genome Sequencing and Drug Susceptibility Test Data in New York","volume":"59","author":"Shea","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e01239-17","DOI":"10.1128\/JCM.01239-17","article-title":"Highly Sensitive Detection of Isoniazid Heteroresistance in Mycobacterium tuberculosis by DeepMelt Assay","volume":"56","author":"Liang","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e02328-20","DOI":"10.1128\/JCM.02328-20","article-title":"On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex","volume":"59","author":"Georghiou","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5588\/ijtldopen.24.0490","article-title":"Updated treatment guidelines for drug-resistant TB: How safe are clofazimine-based regimens?","volume":"1","author":"Pontali","year":"2024","journal-title":"IJTLD Open"},{"key":"ref_45","unstructured":"European Centre for Disease Prevention and Control (2025, July 10). Handbook on Tuberculosis Laboratory Diagnostic Methods in the European Union. Updated 2022. Available online: https:\/\/www.ecdc.europa.eu."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/7\/732\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:13:15Z","timestamp":1760033595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/7\/732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["antibiotics14070732"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14070732","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}